- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03530566
Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery
Prospective Comparative Clinical Study to Evaluate Effectiveness of a Standardized Multidisciplinary Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study population: 25 patients with morbid obesity (BMI ≥ 40 kg / m2) or severe obesity (BMI 35 to 39.9 kg / m2) , with two or more comorbidities, scheduled for bariatric surgery within 3 months, and who will start treatment with the multidisciplinary weight loss program (PnK Method) based on diet, exercise and psychological support.
Patients will be followed-up for 3 months, with the following controls: pre-selection, baseline, month 1, month 2, month 3, and control when hospital discharge.
The treatment schedule in these patients will be as follows: a very low calorie ketogenic diet for at least 1 month or until losing 10% of the weight, and then, a low calorie diet with gradual reintroduction of natural foods for 2 months, until surgery.
The investigators will obtain retrospective data from 25 patients treated with the standard diet who met the same inclusion/exclusion criteria as the patients in this study and who similarly resemble in age, sex and BMI, for comparative analysis (control group).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of both sexes, between 18 and 65 years old
- Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities associated with obesity (type 2 diabetes mellitus, arterial hypertension, obstructive sleep apnea, obesity hypoventilation syndrome, chronic respiratory disease, metabolic syndrome, atrial fibrillation, heart failure, pulmonary hypertension, cardiomyopathy, history of thrombosis, renal failure).
- Patients scheduled for bariatric surgery within 3 months ± 1 week.
- Patients who, regardless of their inclusion in this study, will undergo treatment with the multidisciplinary slimming program in study or standard diet.
- Patients who agree to participate and sign the Informed Consent
Exclusion Criteria:
- Pregnant or lactating women.
- Patients with type 1 diabetes mellitus or on insulin therapy
- Patients with eating disorders, alcoholism, and/or drug addiction.
- Patients with any severe psychological disorder (eg schizophrenia, bipolar disorder).
- Patients receiving dicumarinic anticoagulants (Sintrom®) or cortisone.
- Patients with liver failure.
- Patients with severe kidney failure (gfr <30).
- Patients with hemopathies.
- Patients with cancer.
- Patients with cardiovascular or cerebrovascular disease (heart rate disorders, recent infarction [<6m], unstable angina, decompensated heart failure, recent stroke [<6m]).
- Patients in acute attack of gout.
- Patients with renal lithiasis verified by ultrasound.
- Patients with cholelithiasis verified by ultrasound.
- Patients with depression.
- Patients with electrolyte imbalance, according to medical criteria.
- Patients with orthostatic hypotension.
- Patients with contraindications to surgery
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Pnk group
Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
|
A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
|
|
Control group
Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
|
standard low calorie diet for weight loss
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight loss at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in body weight from baseline to 3 monthes
|
from baseline to 3 monthes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight loss at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in body weight from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Body weight loss at 1 month
Time Frame: from baseline to 1 month
|
Change in body weight from baseline to 1 month
|
from baseline to 1 month
|
|
Change in systolic blood pressure at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in systolic blood pressure from baseline to 3 monthes
|
from baseline to 3 monthes
|
|
Change in diastolic blood pressure at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in diastolic blood pressure from baseline to 3 monthes
|
from baseline to 3 monthes
|
|
Change in systolic blood pressure at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in systolic blood pressure from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Change in diastolyc blood pressure at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in diastolyc blood pressure from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Change in systolic blood pressure at 1 month
Time Frame: from baseline to 1 month
|
Change in systolic blood pressure from baseline to 1 month
|
from baseline to 1 month
|
|
Change in diastolic blood pressure at 1 month
Time Frame: from baseline to 1 month
|
Change in diastolic blood pressure from baseline to 1 month
|
from baseline to 1 month
|
|
Change in blood glucose at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in blood glucose level from baseline to 3 monthes
|
from baseline to 3 monthes
|
|
Change in blood glucose at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in blood glucose level from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Change in blood glucose at 1 month
Time Frame: from baseline to 1 month
|
Change in blood glucose level from baseline to 1 month
|
from baseline to 1 month
|
|
Change in HbA1c at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in HbA1c (Glycated hemoglobin) percentage from baseline to 3 monthes
|
from baseline to 3 monthes
|
|
Change in HbA1c at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in HbA1c (Glycated hemoglobin) percentage from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Change in HbA1c at 1 month
Time Frame: from baseline to 1 month
|
Change in HbA1c (Glycated hemoglobin) percentage from baseline to 1 month
|
from baseline to 1 month
|
|
Change in total cholesterol level at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in blood total cholesterol level from baseline to 3 monthes
|
from baseline to 3 monthes
|
|
Change in total cholesterol level at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in blood total cholesterol level from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Change in total cholesterol level at 1 month
Time Frame: from baseline to 1 month
|
Change in blood total cholesterol level from baseline to 1 months
|
from baseline to 1 month
|
|
Change in triglycerides level at 3 monthes
Time Frame: from baseline to 3 monthes
|
Change in blood triglycerides level from baseline to 3 monthes
|
from baseline to 3 monthes
|
|
Change in triglycerides level at 2 monthes
Time Frame: from baseline to 2 monthes
|
Change in blood triglycerides level from baseline to 2 monthes
|
from baseline to 2 monthes
|
|
Change in triglycerides level at 1 month
Time Frame: from baseline to 1 month
|
Change in blood triglycerides level from baseline to 1 month
|
from baseline to 1 month
|
|
Metabolic Control of type 2 Diabetes at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse metabolic control of type 2 Diabetes at 3 months regarding baseline
|
from baseline to 3 monthes
|
|
Clinical Control of arterial hypertension at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical control of arterial hypertension at 3 months regarding baseline
|
from baseline to 3 monthes
|
|
Clinical Control of Hypercholesterolemia at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical control of Hypercholesterolemia at 3 months regarding baseline
|
from baseline to 3 monthes
|
|
Clinical Control of Hypertriglyceridemia at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical control of Hypertriglyceridemia at 3 months regarding baseline
|
from baseline to 3 monthes
|
|
Improvement of Sleep Apnea Obstructive Syndrome at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Sleep Apnea Obstructive Syndrome, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Chronic Respiratory Disease at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Chronic Respiratory Disease, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Obesity hypoventilation syndrome at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Obesity hypoventilation syndrome, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Metabolic syndrome at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Percentage of patients with better, equal or worse clinical symptoms of Obesity hypoventilation syndrome, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Atrial fibrillation at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Atrial fibrillation, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Cardiac insufficiency at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Cardiac insufficiency, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Pulmonary hypertension at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Pulmonary hypertension, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Cardiomyopathy at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of cardiomyopathy, regarding baseline.
|
from baseline to 3 monthes
|
|
Improvement of Renal insufficiency at 3 months
Time Frame: from baseline to 3 monthes
|
Percentage of patients with better, equal or worse clinical symptoms of Renal insufficiency, regarding baseline.
|
from baseline to 3 monthes
|
|
Obesity Surgery Mortality Risk Score
Time Frame: 3 months
|
Obesity Surgery Mortality Risk Score at the preoperative visit
|
3 months
|
|
Length of surgery
Time Frame: During bariatric surgery
|
Length (in minuts) of bariatric surgery
|
During bariatric surgery
|
|
Length of anesthesia
Time Frame: During bariatric surgery
|
Length (in minuts) of anesthesia during bariatric surgery
|
During bariatric surgery
|
|
Number of patients with intraoperative complications
Time Frame: During bariatric surgery
|
Number of patients with intraoperative complications occurring during bariatric surgery and within the postoperative 24 hours
|
During bariatric surgery
|
|
Number of patients with postoperative complications after bariatric surgery
Time Frame: After bariatric surgery
|
Number of patients with postoperative complications occurring before hospital discharge
|
After bariatric surgery
|
|
Number of total days of hospitalization
Time Frame: After bariatric surgery
|
Number of total days of hospitalization after bariatric surgery
|
After bariatric surgery
|
|
Number of Participants With Adverse Events related to preoperative weight loss treatment
Time Frame: Through 3 months of study
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability of standardized weight-loss programme (PnK® Method)
|
Through 3 months of study
|
|
Number of weight loss treatment dropout rate
Time Frame: from baseline to 3 monthes
|
Number of weight loss treatment dropout rate from baseline to 3 months
|
from baseline to 3 monthes
|
|
Number of patients who refuse bariatric surgery at 3 months
Time Frame: from baseline to 3 monthes
|
Number of patients who refuse bariatric surgery from baseline to 3 months
|
from baseline to 3 monthes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Davide De Carvalho, Ph, Centro Hospitalar Sao Joao do Porto
- Principal Investigator: Paula Freitas, Ph, Centro Hospitalar Sao Joao do Porto
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO-CBP-2017-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.